LONDON, June 12, 2018 /PRNewswire/ --
Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones
The global biosimilars and follow-on biologics market is estimated to have reached $7.70bn in 2017 and expected to grow at a CAGR of 23.8% in the first half of the forecast period. The market is dominated by Biosimilar Monoclonal Antibodies, this submarket is estimated to hold 24% share of this market by 2022.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 335-page report you will receive 131 tables and 68 figures- all unavailable elsewhere.
The 335-page report provides clear detailed insight into the global biosimilars and follow-on biologics market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Biosimilars and Follow-on Biologics Market forecasts from 2018-2028
• Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2028 for 8 individual therapeutic submarkets:
• Monoclonal antibodies (mAbs)
• Fusion proteins
• Insulin
• Erythropoietin (EPO)
• Granulocyte colony-stimulating factor (G-CSF)
• Interferons
• Growth hormones
• Fertility hormones
• This report also shows revenue to 2028 for 12 individual submarkets within the above segments:
• Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab
• Human insulin, insulin analogues, insulin glargine and insulin lispro
• Interferon alfa and interferon beta
• Etanercept
• Our analyses show individual revenue forecasts to 2028 for 12 national markets:
• US
• Japan
• Germany, France, UK, Italy and Spain
• China, India, South Korea, Russia and Brazil
• Our study provides a SWOT analysis of the biosimilars and follow-on biologics market.
• Our study discusses pressures, opportunities and other events affecting the biosimilars industry and market, including these influences:
• Strategies for developing biosimilars - needs, demand, challenges and opportunities
• Guidelines from regulators (FDA, EMA and others)
• Patent challenges and data exclusivity for biopharmaceuticals
• Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers and increasing demand for lower-cost biologicals
• Developments in technology and operations for biosimilar drug production.
Visiongain's study is intended for anyone requiring commercial analyses for the biosimilars and follow-on biologics market. You find data, trends and predictions.
Buy our report today Global Biosimilars and Follow-On Biologics Market 2018-2028: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones.
To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongaim.com or refer to our website : https://www.visiongain.com/Report/2212/Global-Biosimilars-and-Follow-On-Biologics-Market-2018-2028
Companies Listed
Allergan
Allozyne
Alteogen
Alvogen
Amarey Novamedical
Amega Biotech
Amgen
Apotex
Astellas Pharma
AstraZeneca
Avesthagen
Baxter
Bayer
Beijing Four Rings
Beijing SL Pharmaceutical
Biocad
Bioceuticals
Biogen
BioGenomics
Biolab
Bionovis
BioPartners
Biosidus
Bioton
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Cambridge Antibody Technology
CCL Pharmaceuticals
CCM Duopharma
Celltrion
Centocor Ortho Biotech
Chong Kun Dang
Chugai
CinnaGen.
Coherus BioSciences
Compass Biotechnologies
Cristália
CT Arzneimittel
Cyplasin
Daiichi Sankyo
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Egis Pharmaceuticals
Eisai
Eli Lilly
Elpen Pharmaceutical
Emcure Pharmaceuticals
EMS
Epirus
Eurofarma
Express Scripts
FibroGen
Finox Biotech
Fuji Pharma
Gan & Lee
Genetech
Genexine
Gennova
GenSci
Genzyme
Geropharm
Gilead Sciences
GlaxoSmithKline
Hangzhou Jiuyuan Gene Engineering Co.
Hanmi Pharmaceutical
Hanwha Chemical
Haselmeier
Health Canada
Helius Biotech
Hexal
Hindustan Antibiotic
Hospira
Hualida Biotech
Hypermarcas
IGES Institute
Intas Biopharmaceuticals
inVentiv Health
JCR Pharmaceuticals
Johnson & Johnson
Kabi
Kemwell Biopharma
Kissea
Koçak Farma
Kwizda Pharma
Kyowa Hakko Kirin
Landsteiner Scientific
LG Life Sciences
Libbs
LKM SA
Lonza
Mabion
Marvel Life Sciences
MEDICE Arzneimittel Pütter
Merck (MSD)
Merck KGaA
Merck Serono
Minapharm
Mitsubishi Tanabe
Mochida Pharmaceutical
Momenta Pharmaceuticals
Mycenax Biotech
Mylan
Nichi-Iko
Nippion Kayaku
Novartis
Novo Nordisk
Nuron Biotech
Oncobiologics
Ortho Pharmaceutical
Orygen
PanGen Biotech
Pfenex
Pfizer
Pharmapark
Pharmstandard
PRA International
Pro Generika
PROBIOMED
Qilu Pharmaceutical
Quintiles
Ranbaxy Laboratories
RAND Corporation
Ratiopharm
Regeneron Pharmaceuticals
Reliance GeneMedix
Reliance Life Sciences (RLS)
Rentschler Biotechnologie
Roche
Samsung Bioepis
Samsung BioLogics
Sandoz
Sanofi
SciGen
Shandong Kexing Pharma
Shanghai Celgen Biopharmaceutical
Shanghai CP Guojian
Shanghai Fosun
Shantha Biotechnics
Shinogi
Sicor Biotech
Sothema Laboratories
Spectrum Pharmaceuticals
STADA Arzneimittel
Stragen Pharma
Strides Arcolab
Syngene International
Synthon Biopharmaceuticals
Takeda
Teva
Tianjin Hualida Biotechnology
Tonghua Dongbao
TSH Biopharm Corp
União Química
USV Biologics
Virchow Biotech
Wanbang Biopharmaceuticals
Wockhardt
Xiamen Amoytop Biotech
Zenotech
Zhejian Huahai Pharmaceutical
Zuventus
Zydus Biovation
Zydus Cadila
To see a report overview please e-mail Sara Peerun on sara.peerun@visiongaim.com
SOURCE Visiongain
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article